利拉鲁肽可降低小鼠动脉粥样硬化中内皮血管细胞黏附分子-1水平，且与血糖水平无关。

Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels.

作者信息

Punjabi Mukesh, Kosareva Alexandra, Xu Lifen, Ochoa-Espinosa Amanda, Decembrini Sarah, Hofmann Georg, Wyttenbach Samira, Rolin Bidda, Nyberg Michael, Kaufmann Beat A

机构信息

Cardiovascular Molecular Imaging, Department of Biomedicine, University of Basel, Basel, Switzerland.

Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.

出版信息

JACC Basic Transl Sci. 2022 Dec 7;8(2):189-200. doi: 10.1016/j.jacbts.2022.08.002. eCollection 2023 Feb.

The authors determined the effect of the GLP-1 receptor agonist liraglutide on endothelial surface expression of vascular cell adhesion molecule (VCAM)-1 in murine apolipoprotein E knockout atherosclerosis. Contrast-enhanced ultrasound molecular imaging using microbubbles targeted to VCAM-1 and control microbubbles showed a 3-fold increase in endothelial surface VCAM-1 signal in vehicle-treated animals, whereas in the liraglutide-treated animals the signal ratio remained around 1 throughout the study. Liraglutide had no influence on low-density lipoprotein cholesterol or glycated hemoglobin, but reduced TNF-α, IL-1β, MCP-1, and OPN. Aortic plaque lesion area and luminal VCAM-1 expression on immunohistology were reduced under liraglutide treatment.

作者们确定了胰高血糖素样肽-1（GLP-1）受体激动剂利拉鲁肽对小鼠载脂蛋白E基因敲除动脉粥样硬化模型中血管细胞黏附分子（VCAM）-1在内皮表面表达的影响。使用靶向VCAM-1的微泡和对照微泡进行的超声分子成像显示，在接受载体治疗的动物中，内皮表面VCAM-1信号增加了3倍，而在接受利拉鲁肽治疗的动物中，整个研究过程中信号比率保持在1左右。利拉鲁肽对低密度脂蛋白胆固醇或糖化血红蛋白没有影响，但降低了肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、单核细胞趋化蛋白-1（MCP-1）和骨桥蛋白（OPN）。在利拉鲁肽治疗下，免疫组织化学检测显示主动脉斑块病变面积和管腔VCAM-1表达降低。